Your browser doesn't support javascript.
loading
Apathy in Parkinson's Disease: Clinical Patterns and Neurobiological Basis.
Béreau, Matthieu; Van Waes, Vincent; Servant, Mathieu; Magnin, Eloi; Tatu, Laurent; Anheim, Mathieu.
Afiliación
  • Béreau M; Département de Neurologie, CHU de Besançon, 25000 Besançon, France.
  • Van Waes V; Université de Franche-Comté, LINC Laboratoire de Recherches Intégratives en Neurosciences et Psychologie Cognitive, 25000 Besançon, France.
  • Servant M; Université de Franche-Comté, LINC Laboratoire de Recherches Intégratives en Neurosciences et Psychologie Cognitive, 25000 Besançon, France.
  • Magnin E; Université de Franche-Comté, LINC Laboratoire de Recherches Intégratives en Neurosciences et Psychologie Cognitive, 25000 Besançon, France.
  • Tatu L; Département de Neurologie, CHU de Besançon, 25000 Besançon, France.
  • Anheim M; Université de Franche-Comté, LINC Laboratoire de Recherches Intégratives en Neurosciences et Psychologie Cognitive, 25000 Besançon, France.
Cells ; 12(12)2023 06 10.
Article en En | MEDLINE | ID: mdl-37371068
ABSTRACT
Apathy is commonly defined as a loss of motivation leading to a reduction in goal-directed behaviors. This multidimensional syndrome, which includes cognitive, emotional and behavioral components, is one of the most prevalent neuropsychiatric features of Parkinson's disease (PD). It has been established that the prevalence of apathy increases as PD progresses. However, the pathophysiology and anatomic substrate of this syndrome remain unclear. Apathy seems to be underpinned by impaired anatomical structures that link the prefrontal cortex with the limbic system. It can be encountered in the prodromal stage of the disease and in fluctuating PD patients receiving bilateral chronic subthalamic nucleus stimulation. In these stages, apathy may be considered as a disorder of motivation that embodies amotivational behavioral syndrome, is underpinned by combined dopaminergic and serotonergic denervation and is dopa-responsive. In contrast, in advanced PD patients, apathy may be considered as cognitive apathy that announces cognitive decline and PD dementia, is underpinned by diffuse neurotransmitter system dysfunction and Lewy pathology spreading and is no longer dopa-responsive. In this review, we discuss the clinical patterns of apathy and their treatment, the neurobiological basis of apathy, the potential role of the anatomical structures involved and the pathways in motivational and cognitive apathy.
Asunto(s)
Palabras clave

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Enfermedad de Parkinson / Apatía Tipo de estudio: Risk_factors_studies Límite: Humans Idioma: En Revista: Cells Año: 2023 Tipo del documento: Article País de afiliación: Francia

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Enfermedad de Parkinson / Apatía Tipo de estudio: Risk_factors_studies Límite: Humans Idioma: En Revista: Cells Año: 2023 Tipo del documento: Article País de afiliación: Francia